Wednesday, July 8, 2026

Drug profile · INN

cisplatin

cisplatin (CISPLATIN ACCORD) is a dna inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

FDA: approved TGA: approved NMPA: clinical trials
US status approved
Patents linked 7
Pipeline programs 216
News articles 0
Drug details — cisplatin
US status
approved
Class
Route
INJECTION
Patents
7
Programs
216
Data quality
0.89

Quick answer

cisplatin (CISPLATIN ACCORD) is a dna inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN cisplatin
Brand CISPLATIN ACCORD
Mechanism DNA inhibitor
Target DNA
Route INJECTION
Formulation INJECTABLE

Mechanism of action

DNA inhibitor

Primary target: DNA

Approval history

Authority Status Date
FDA approved
TGA approved
NMPA clinical trials

Pipeline programs

  1. 1407-GUCG Phase 3 · Ningbo Cancer Hospital · Progressive or recurrent germ cell tumor (measurable or non-
  2. 1479-0008 Phase 3 · Boehringer Ingelheim · non-squamous non-small cell lung cancer
  3. 17000139BLC3001 Phase 3 · Janssen-Cilag International N.V · Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
  4. 2019/2894 Phase 3 · George Institute for · Patients with High Risk Neuroblastoma
  5. 20200041 Phase 3 · Amgen · Extensive stage small cell lung cancer (ES-SCLC)
  6. 2020HXFH037 Phase 3 · Chinese Academy of · Nasopharyngeal Carcinoma
  7. 22615 Phase 3 · Bayer · Advanced non-small cell lung cancer with HER2 (ERBB2) mutati
  8. 61186372HNC3001 Phase 3 · Janssen-Cilag International N.V · Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous

Related & competitor drugs

  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)
  1. US 11013740

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 10272084

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 8703756

    Synthetic procedure and cancer treatment with cisplatin derivatives

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. EP 2678011

    ANTITUMORIGENE KOMBINATON, DIE CABAZITAXEL UND CISPLATIN UMFASST

    Expires Tue Dec 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. EP 2620148

    Antitumorkombination mit Cabazitaxel und Cisplatin

    Expires Tue Jul 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. EP 2491925

    Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst

    Expires Tue Aug 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 7700134

    Prevention of cisplatin induced deafness

    Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is cisplatin?

cisplatin (CISPLATIN ACCORD) is a dna inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for cisplatin?

CISPLATIN ACCORD is a marketed brand name for cisplatin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cisplatin?

cisplatin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.